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Background: Raltegravir (Isentress®)(RALT) has demonstrated excellent efficacy in both treatment-experienced and
naïve patients with HIV-1 infection, and is the first strand transfer integrase inhibitor to be approved for use in HIV
infected adults worldwide. Since the in vivo efficacy of this class of antiviral drugs depends on their access to
intracellular sites where HIV-1 replicates, we analyzed the biological effects induced by RALT on human MDR cell
systems expressing multidrug transporter MDR1-P-glycoprotein (MDR1-Pgp).
Methods: Our study about RALT was performed by using a set of consolidated methodologies suitable for
evaluating the MDR1-Pgp substrate nature of chemical and biological agents, namely: i) assay of drug efflux
function; ii) analysis of MDR reversing capability by using cell proliferation assays; iii) monoclonal antibody UIC2
(mAb) shift test, as a sensitive assay to analyze conformational transition associated with MDR1-Pgp function; and
iv) induction of MDR1-Pgp expression in MDR cell variant subjected to RALT exposure.
Results: Functional assays demonstrated that the presence of RALT does not remarkably interfere with the efflux
mechanism of CEM-VBL100 and HL60 MDR cells. Accordingly, cell proliferation assays clearly indicated that RALT
does not revert MDR phenotype in human MDR1-Pgp expressing cells. Furthermore, exposure of CEM-VBL10 cells
to RALT does not induce MDR1-Pgp functional conformation intercepted by monoclonal antibody (mAb) UIC2
binding; nor does exposure to RALT increase the expression of this drug transporter in MDR1-Pgp expressing cells.
Conclusions: No evidence of RALT interaction with human MDR1-Pgp was observed in the in vitro MDR cell
systems used in the present investigation, this incorporating all sets of studies recommended by the FDA
guidelines. Taken in aggregate, these data suggest that RALT may express its curative potential in all sites were
HIV-1 penetrates, including the MDR1-Pgp protected blood/tissue barrier. Moreover RALT, evading MDR1-Pgp drug
efflux function, would not interfere with pharmacokinetic profiles of co-administered MDR1-Pgp substrate
antiretroviral drugs.
Keywords: Raltegravir, MDR1-Pgp, Drug substrate, MDR1-Pgp induction, Antiretroviral treatmentBackground
The suboptimal penetration of antiretroviral agents into
sanctuary sites such as the central nervous system or into
target CD4 cells may contribute to viral persistency. Drug
transporters are viewed as one of the major mechanisms
which account for suboptimal tissue concentrations of
antiretroviral agents. MDR1-P-glycoprotein (MDR1-Pgp,
ABCB1), as well as other ABC family members of
structurally and functionally related proteins, is a plasma
membrane transporter which participates in the transport* Correspondence: Maurizio.Cianfriglia@iss.it
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reproduction in any medium, provided the orof a wide variety of drugs, including anti-cancer chemo-
therapeutics [1] and antiretroviral compounds [2]. The
antiviral agent Raltegravir (Isentress®)(RALT) is the first
integrase inhibitor (IIN) to be approved for treatment of
HIV infection in adults [3,4]. However, the involvement of
human drug transporters in RALT absorption, disposition,
metabolism and excretion (ADME) has not been fully
investigated. RALT has been described as being an
MDR1-Pgp substrate [5,6], but there are still few data
in the public domain, which are not even definitive.
As for all known anti-retrovirals, the emergence of viral
mutations conferring resistance to antiretroviral agents
has been documented for this compound [7]. However,Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of MDR1-Pgp and/or other members of the ABC trans-
porter family which, through intercepting drugs by
means of the binding transport sites within the MDR1-
Pgp binding pocket, delivers them out of the cells via an
ATP dependent mechanism [8,9]. MDR1-Pgp was initially
studied in the setting of anticancer treatment; it was
identified as the biological entity conferring the multidrug
resistance (MDR) in tumor cells, this by reducing the level
of cytotoxic drug under sub-lethal concentration [10].
In vitro and in vivo studies have shown that all protease
inhibitors display a high affinity for MDR1-Pgp [11-13],
as well the CCR5 inhibitor maraviroc [6,14] and quinolonyl
diketoacid derivatives (DKA) with anti-integrase activity
[15]. These latter compounds, although different in chem-
ical structure from RALT, exert a similar inhibition on
strand transfer activity of HIV-1 integrase. Since in vivo
efficacy of this class of drugs depends on their access to
intracellular sites where HIV-1 replicates, and given
that limited information exists on RALT interaction
with human MDR1-Pgp expressing cells, we performed
a set of well-established in vitro studies on the human
CD4 positive lymphoblastoid CCRF-CEM cell line and
its derivative MDR variants, in line with FDA concept
paper on drug interactions [16]. In order to strengthen
the data about the interaction between RALT and human
MDR1-Pgp, we incorporated an additional human MDR
cell system in this investigation. In line with FDA recom-
mendations, we evaluated RALT as substrate, inhibitor
and inducer of MDR1-Pgp by performing the following
studies: i) inhibition of drug transport function by using the
classical efflux assay [17]; ii) down-modulation of multidrug
resistance (MDR) phenotype in cell proliferation assay
[18]; iii) up-modulation of the monoclonal antibody
(mAb) UIC2 epitope in MDR cells during MDR1-Pgp-me-
diated drug transport [19]; and iv) induction of MDR1-
Pgp expression by exposing MDR CEM-VBL10 cells to
MDR1-Pgp substrates [20].
Results and discussion
Assessment of MDR1-Pgp expression level in human MDR
cell lines
The studies for evaluating the functional and biological
interaction of RALT with human MDR1-Pgp were con-
ducted by using two different human cell systems con-
sisting of: a) the lymphoblastoid CD4 positive cell line
CCRF-CEM and its derivative MDR variants CEM-VBL10
and CEM-VBL100 expressing increased level of MDR1-Pgp
binding sites and relative resistance; b) the drug sensitive/
resistant HL60 and HL60-DNR cell pairs of acute myeloid
leukemia (AML) origin. The MDR phenotype of such
cells was tested and monitored by the highly specific
mAb MM4.17 to the external MDR1-Pgp domain [21].
The binding profiles shown in Figure 1 confirm theMDR nature of CEM-VBL10, CEM VBL100 and HL60-
DNR cells, while the parental drug sensitive cell lines
CCRF-CEM and HL60 were not recognized by the
mAb, thereby indicating the absence of detectable MDR1-
Pgp molecules.
Drug efflux
Rhodamine 123 (Rh123) is a fluorescent marker substrate
for MDR1-Pgp; incubation of MDR1-Pgp-positive cells
with this drug, followed by washing and further incubation
at 37°C, results in a diminished fluorescence profile due to
the active drug transport exerted by the MDR1-Pgp efflux
system expressed in MDR cells. The presence of a MDR1-
Pgp inhibitor such as Verapamil (Vrp) during incubation
and/or drug extrusion, restores Rh123 fluorescence [17].
As shown in Figure 2, differently from the potent MDR1-
Pgp drug transporter inhibitor Vrp, RALT is not capable at
the indicated concentrations to inhibit drug efflux and does
not produce Rh123 accumulation in both CEM-VBL100
and HL60-DNR MDR cells. In order to verify the absence
of inhibitory effect of RALT on MDR1-Pgp function,
additional drug efflux assays were performed with
VBL-bodipy and Calcein-AM: these studies showed that
the drug does not affect the efflux of the fluorescent dye
substrate VBL-bodipy while a little shift involving 5-10%
of the Calcein-AM treated cells was observed (Additional
file 1: Figure S1). Therefore, these data confirm the absence
of a remarkable inhibitory activity of RALT on MDR1-Pgp
expressing cells.
Proliferation assay
To evaluate RALT’s potential ability to down modulate
the MDR phenotype, standard proliferation assays were
used. The experiments were performed by using increasing
concentrations of the potent cytotoxic drug vinblastine
(VBL) in presence and absence of RALT and the MDR
reversing agent Vrp. The concentration of RALT equal
to 12.5 μg/mL used in proliferation assays, is twice that
observed in plasma of patients treated with conventional
RALT dosage [22]. The study was conducted both on drug
sensitive parental cells and their derivative variants CEM-
VBL100 and HL60-DNR. The growth curves shown in the
Figure 3 demonstrate that RALT does not induce any
modulation of MDR phenotype on CEM-VBL100 and
HL60-DNR cell lines; this suggests that this antiviral
drug does not interfere with MDR1-Pgp drug transport
function. The cell growth patterns of CEM-VBL100 cells
(Figure 3, Panel A) obtained in the presence of VBL and
VBL plus RALT are similar as evidenced by their IC50
values (0.226 ± 0.053 μg/mL and 0.201 ± 0.047 μg/mL,
respectively) (Figure 3, Panel B). Likewise, the cell growth
profiles obtained with HL60-DNR in VBL and VBL plus
RALT (Figure 3, Panel A) containing cell culture conditions
















Figure 1 MDR cell lines. MDR1-Pgp expression was determined by the highly specific mAb MM4.17. In Panel A, the binding profiles obtained
by staining the parental drug sensitive cell line CCRF-CEM and its derivative MDR variants (CEM-VBL10 and CEM-VBL100) are shown. In Panel B,
there are the binding profiles of the AML drug sensitive/resistant cell pairs HL60 and HL60-DNR.
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ively) (Figure 3, Panel B). In contrast, the growth curve
profiles of both CEM-VBL100 and HL60-DNR MDR cells
cultured in the presence of VBL and the MDR reversing
agent Vrp, show a dramatic inhibition of cell proliferation
caused by down modulation of MDR1-Pgp activity. The
IC50 values calculated for the CEM-VBL100 and HL60-
DNR in the presence of Vrp were 0.0052 ± 0.0010 μg/mL
and 0.0050 ± 0.0010 μg/mL, respectively (Figure 3, Panels
A and B). The cell growth curve patterns of the parental
drug sensitive CCRF-CEM and HL60 cell lines show, as
expected, a higher susceptibility to VBL, while no further
biological effect was observed in the presence of the
various combinations of drugs (Figure 3, Panels A and
B). In order to better elucidate the potential interaction
of RALT with MDR1-Pgp, we exposed the panel of cell
lines to different amounts of RALT ranging from 0.1 to
100 μg/mL. In this case, the parental drug sensitive
cells seem to be more susceptible to RALT in respect to
their MDR variants (Figure 4). Considering the small
magnitude of growth inhibition, this phenomenon may
simply reflect a different drug susceptibility among the
cell types observed in in vitro conditions. However, it
cannot be ruled out that RALT may behave as a weak
substrate, and that the MDR1-Pgp molecules expressed
on MDR cells act as a drug transporter lowering the
drug concentration and its related cytotoxic effect.
This result might justify the observation of the small
fraction of MDR cell population retaining the dye sub-
strate Calcein-AM in the drug efflux studies (Additional
file 1: Figure S1). Furthermore, this hypothesis may be in
partial in agreement with previous published findings
showing that a reduction of RALT efflux of only 32% was
observed when the potent reversing agent Tariquidar was
used to inhibit ABCB1 in CEM VBL100 cells [5]. To
this regard, it should here mentioned as FDA guidelines
recommend that a drug should achieve an efflux ratiogreater than a 50% reduction when an ABCB1 inhibitor
is used in order for ABCB1 transport to be considered
relevant in vivo [16]. To further investigate the RALT
modulating effect on MDR1-Pgp, the mAb UIC2 shift
assay was used. This test is a useful tool for detecting
conformational changes associated with the function
of MDR1-Pgp and provides a potentially useful diag-
nostic test for both the expression and the function of
MDR1-Pgp [19].
UIC2 shift assay
The UIC2 mAb (IgG2a) reacts with the extracellular
moiety of MDR1-Pgp and inhibits MDR1-Pgp-mediated
efflux of all tested MDR chemotherapeutic drugs. It has
been shown that the reactivity of UIC2 mAb on MDR cells
is enhanced in the presence of a large array of compounds
recognized as MDR1-Pgp substrates which include cyto-
toxic agents together with certain classes of MDR reversing
agents (Verapamil, Quinidine, Cyclosporine-A) [19]. This
phenomenon has been used to develop a highly specific
and sensitive method to confirm the MDR1-Pgp substrate
and MDR reversal agent nature of several chemical agents
[23,24]. Therefore, to elucidate the RALT/MDR1-Pgp
interaction, we took advantage of the mAb UIC2 ability
to bind with increased affinity to its target in the pres-
ence of MDR1-Pgp modulators due to conformational
changes in functioning MDR1-Pgp. In order to highlight
this phenomenon, we used the cell line CEM-VBL10 as
MDR1-Pgp expressing cells instead of CEM-VBL100 cells,
because of the former’s relatively lower number of
MDR1-Pgp binding sites/cell (10,000 binding sites/cell)
[M. Cianfriglia, unpublished]. In general, cell lines with
a higher level of MDR1-Pgp molecules require higher
concentrations of MDR1-Pgp substrates for maximal
stimulation [25]. The results of this study show a signifi-
cant induction of mAb UIC2 binding on CEM-VBL10
































Figure 2 Evaluation of Rh123 transport inhibition mediated by RALT. The efflux of the dye MDR1-Pgp substrate Rh123 in CEM-VBL100 and
HL60-DNR MDR cells was monitored in drug-free conditions (blue histogram), in the presence of the potent MDR1-Pgp blocker Vrp (2.5 μg/mL)
(green histogram), and following incubation with RALT (red histogram) dissolved in DMSO or H2O at the concentrations shown on the right side
of the panels.
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and 50 μg/mL of RALT (Figure 5, Panel A and B).
Induction of MDR1-Pgp expression in MDR cells
Since the discovery of the simultaneous resistance of
tumor cells to a large array of anti-cancer compounds in
the late 1970s, the inhibition of MDR1-Pgp conferring
the MDR has become an attractive therapeutic strategy
in order to de novo sensitize tumor cells to anticancer
drugs in cancer patients [26]. However, drug/drug interac-
tions are critical factors in all therapeutic regimens, the
co-administration of MDR modulators with drugs that are
MDR1-Pgp substrates needing to be balanced with lower
drug concentrations to avoid unpredictable side effects
[27]. In this regard, the FDA concept paper on druginteractions recommends that new drug candidates should
be evaluated as substrates, inhibitors, and also as inducers
of MDR1-Pgp [16]. We therefore decided to study the
induction of MDR1-Pgp after a prolonged exposure to
various concentrations of RALT of CEM-VBL10 cells,
which are very prone to modulate MDR1-Pgp expression
in the presence of cytotoxic drugs and/or MDR1-Pgp sub-
strates. In parallel experiments, the cells were cultured
with increasing amounts of the potent MDR1-Pgp inducer
and substrate VBL. The relationship of RALT and VLB
concentrations are absolutely empirical, but congruous to
demonstrate different induction phenomena exerted by
these drugs. In the presence of VBL, CEM-VBL10 cells
"respond" by increasing the percentage of MDR cells in
relationship with drug concentration, as evidenced by the
Figure 3 MDR chemosensitization. In the upper part of the figure the dose-response growth curves of drug sensitive parental cell lines
(CCRF-CEM and HL60) and their derivative MDR variants (CEM-VBL100 and HL60/DNR) are shown (Panel A). The cells were cultured for 72 h in
medium containing increasing concentrations of VBL alone (open circles), VBL plus 12.5 μg/mL of the IIN RALT (open triangles), and VBL plus
2.5 μg/mL of the MDR1-Pgp blocker Vrp (open squares). In the lower part of the figure (Panel B), the IC50 values (concentrations of the
compound that inhibits cell growth by 50%) for each cell culture condition are reported. Values are means of three independent experiments,
each done in triplicate.
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with the MDR1-Pgp specific antibody MM4.17 (left part
of Figure 6). In contrast, RALT is totally ineffective in
inducing MDR1-Pgp expression up to the maximum
tested concentration of 50 μg/mL (right part of Figure 6).
By exposing CEM-VBL10 to an additional increase of drug
concentrations (100 ng/mL of VBL and 100 μg/mL ofRALT), a large phenomenon of cell death in the VBL
containing cultures was observed, but no particular
biological effect with regard to the RALT (data not shown).
Several clinical trials have shown a sustained antiretro-
viral effect and a good tolerability of RALT in naive and
treatment-experienced HIV-1 infected patients [28]. Previ-
ous investigations have already reported that RALT has a
Figure 4 Growth inhibition assay. Concentration-dependent effect
of the RALT on proliferation rate of drug sensitive/resistant cell pairs
CCRF-CEM and HL60 (Panels A and B, respectively) after 72 h of
culture. The figure depicts one representative experiment, and data
are expressed as % of untreated control cells with each
concentration tested in triplicate.
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[6]. Update studies on pharmacology profile of RALT
are described in the recently published review article
by Brainard et al. [29], which reports that RALT is not an
inhibitor of the major CYP isozymes, including CYP3A4,
UGTs, and MDR1-Pgp. Additionally, it has been reported
that RALT is not an inducer of CYP3A4 RNA expressionFigure 5 Modulation of the UIC2 epitope. In the Panel A and B the bin
(red histogram); incubation of the cells with RALT (25 and 50 μg/mL) does
marked shift of mAb binding UIC2 is observed incubating CEM-VBL10 cells
represents cells stained with secondary antibody alone.or CYP3A4-dependent testosterone 6 beta-hydroxylase
activity [14]. In previous studies conducted by our group,
a series of diketoacid-containing derivatives (DKA)
functioning as inhibitors of HIV-1 integrase have been
described as being MDR1-Pgp ABCB1 substrates [15]
with strong MDR1-Pgp inhibitory activity. Elvitegravir
[4,6], which has a biochemical formulation similar to
DKA, shows marked drug interaction with MDR1-Pgp
multi-drug transporter and acts as a strong MDR revers-
ing agent [15]. Our study performed with human MDR
cell lines clearly shows that the RALT compound does not
inhibit MDR1-Pgp mediated drug transport function. The
different level of cytotoxic effect exerted by RALT on drug
sensitive/resistant cell pairs (Figure 4) and the low shift
of a small fraction of MDR cell population incubated
in presence of Calcein-AM may be cell type and dye-
substrate related, and not sufficient to establish the exist-
ence of an authentic interaction with MDR1-Pgp. In this
context, Zambruski et al. [6], include elvitegravir, vicriviroc
and to a lesser extent RALT in the list of MDR1-Pgp sub-
strates. However, our own findings concerning RALT seem
to suggest otherwise, a possible explanation being in the
different cell system used and in the interpretation of data.
Again in this regard, Moss et al. showed that RALT has
minimal interactions with known drug transporters, and
that the rate of MDR1-Pgp-mediated transport in vitro
is so low that the potential for interactions of this entity
is expected to be small [5]. The very low rate of RALT
transport by MDR1-Pgp expressing cells may explain
the absence of major drug interactions with known
potent MDR1-Pgp inhibitors. Furthermore, very recently,
Tempestilli et al., [30] showed that darunavir, unlike RALT,
may modify the expression and functionality of MDR1-Pgp
on human lymphocytes. Taken in aggregate, the above
mentioned studies are consistent with a previous report
where the co-administration of low-dose ritonavir had
no major effect on RALT pharmacokinetics, and no dose
adjustment was required for patients [31].ding profiles of the mAb UIC2 on CEM-VBL10 MDR cells are shown
not interfere with mAb UIC2 binding (green histogram). Conversely, a
with VBL (10 μg/mL) (Panel C, green histogram). The filled profile
Figure 6 MDR1-Pgp drug induction assay. In the left part of the figure, the shift of the MDR1-Pgp binding profile (shaded histogram) is
parallel with the increase of VBL concentration. In the right part of the figure, RALT treatment is ineffective in all tested concentrations in up-
modulating the MDR1-Pgp expression (empty histogram). In both experiments the highly specific mAb MM4.17 was used for staining procedures.
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known efficacy and safety, RALT may present an advantage
in respect to other anti-retrovirals that are MDR1-Pgp
substrate. Indeed, RALT’s biological properties may endow
it with a higher therapeutic potential against HIV-1 residing
in sanctuaries sites pharmacologically protected by MDR1-
Pgp expressed on blood tissue barriers. However, in
this context, it is important to remember that, despite
MDR1-Pgp is the first discovered and probably the most
widely studied ABC transporter protein, there are other
ABC transporters involved in clinical MDR and in drug
absorption and distribution; these include multidrug
resistance proteins (MRPs, ABCCs) and breast cancer
resistant protein (BCRP, ABCG2) [32,33]. In particular,
MRP1, MRP2, MRP4 and BCRP/ABCG2, together with
MDR1-Pgp, are present on many barrier sites such as
the blood-brain barrier and on many circulating cells such
as lymphocytes, and consequently they could contributeto reduce antiretroviral agents in sanctuary or HIV-1 target
sites [34].
Conclusions
Our investigations demonstrate that RALT is ineffective
in inhibiting drug efflux and in down-modulating the
MDR phenotype of human CEM and HL60 MDR cells to
an extent considered relevant in vivo by FDA guidelines
[16]. In addition, exposure of CEM-VBL10 to RALT does
not induce the functional conformation of MDR1-Pgp
intercepted by the shift of UIC2 mAb binding. Further-
more, in contrast to other licensed anti-HIV-1 drugs such
as the protease inhibitors, RALT has proved to be ineffect-
ive in inducing an increase of MDR1-Pgp expression
level in MDR cells in culture conditions. The absence of
remarkable RALT/MDR1-Pgp interaction may represent
a medically relevant property, although at present its
impact in the clinical setting is not totally clear. Further
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underlying the profound functional differences of RALT
in comparison with other IINs which behave as MDR-Pgp
substrates and MDR reversing agents and, ii) the potential




The RALT was a kind gift of the Merck company
(Pomezia, Rome, Italy); Verapamil (Isoptin) was purchased
by Abbott (Latina, Italy); Vinblastine (Velbe) by Eli Lilly
(Paris, France); Rhodamine-123 was purchased from Sigma
(St. Louis, MO). Vinblastine-bodipy (VBL-bodipy) and
Calcein acetoxymethlyl ester (Calcein-AM) were purchased
from Molecular Probes (Eugene, OH).
Cell lines
The multidrug resistant (MDR) variants CEM-VBL10 and
CEM-VBL100 cells were isolated by stepwise selection
of the parental drug sensitive CCRF-CEM (CEM) in the
presence of increasing concentrations of VBL [up to the
final concentration of 10 and 100 ng/mL, respectively].
Cells were grown under standard conditions for mamma-
lian cells cultured in suspension. The basic medium (BM)
for cell culturing consisted of RPMI-1640 supplemented
with 10% foetal calf serum (FCS), L-glutamine (2 mM)
penicillin (100 U/mL) and streptomycin (100 U/mL). All
these components were purchased from Hyclone (Logan,
Utah, USA). Identical culture conditions were adopted for
the multidrug resistant (MDR) variants HL60-DNR, kindly
provided by Dr. Ruoping Tang (Hopitaux de Paris, Paris,
France).
MDR efflux assay
CEM-VBL100 and HL60-DNR cell lines (1 × 106) were
loaded with Rh123 (5 μg/mL)(or with VBL-bodipy,
50 ng/mL, or Calcein-AM, 50 ng/mL) in 1 mL of BM in
the presence of RALT (concentrations: 50 and 25 μg/mL)
or Vrp (2.5 μg/mL) for 1 h at 37°C. The cells were
incubated with Rh123 at the indicated concentrations
or with drug diluents (DMSO: 0.5%; H2O). At the end
of incubation, the cells were washed in serum-free
medium and re-suspended in BM in the presence of
RALT or Vrp (drug diluents was added in control samples)
for a further 1 h at 37°C. Finally, cells were washed
twice with ice cold phosphate-buffered saline (PBS)/FACS,
and analyzed in a flow cytometer (FACScan, Becton
Dickinson, San Josè, CA).
Cell proliferation assay
The parental drug sensitive and their MDR derivative
cell lines in exponential phase of growth were collected,
extensively washed with warm RPMI-1640 and seeded(in triplicate) in 96-well microtiter Costar plates (Costar,
Rochester, NY) at a density of 5×103 cells/mL.
For MDR chemosensitization studies, the cells were
cultured in BM containing increasing concentrations
of VBL ranging from 0 to 10 μg/mL; in parallel, MDR
cell cultures containing the different concentrations of
VBL were grown in the presence of RALT (12.5 μg/mL)
dissolved in water. As a control the MDR reversing agent
Vrp was used at the concentration of 2.5 μg/mL in an
additionally parallel culture. In growth inhibition assays
RALT was tested alone at 4 concentrations spread over a
range between 0 and 100 μg/mL. For all above described
experiments cell survival was determined by WST-1 assay
(PreMix WST-1 cell proliferation kit, Vinci Biochem,
Firenze, Italy) after 72 h treatment at 37˚C in 5% CO2.
The values describing the concentration-response profiles
are calculated as % of appropriated control and represent
the mean of three independent experiments, each done in
triplicate. The GraphPad Prism statistical analysis program
was used.
Monoclonal antibodies and UIC-2 Shift assay
The mAb UIC2 [19] was kindly provided by Dr. E.
Mechetner (Chemicon Inc, Temecula, CA). For deter-
mination of MDR1-Pgp expression, the mAb MM4.17
recognizing an extracellular MDR1-P-gp epitope on
intact/living human MDR cells [21] was used (data not
shown). Both UIC2 and MM4.17 mAbs were used in a
highly purified form. The UIC2 shift assay was performed
under physiological conditions as previously described
[19]. CEM-VBL10 cells (1×106) were resuspended in 1 mL
of PBS containing 2% FCS and allowed to equilibrate at
37°C in a water bath for 10 min. The RALT was added
to samples (final concentration 25 and 50 μg/mL) and
incubated for additional 15 min at 37°C with purified
UIC2 mAb (final concentration 12.5 μg/mL). VBL (10 μg/
mL), a well known UIC2 shifting agent, was used as posi-
tive control do detect the conformation of MDR1-Pgp
during drug efflux function. Cells were then washed twice
in ice-cold PBS containing 2% FCS with 0.01% sodium
azide (Shift Stop Buffer, SSB), stained on ice in SSB
for additional 15 min with 5 μg/mL of fluorescein-
conjugated goat-antimouse antibody (FITC-GAM, Cappel,
West Chester, Pa, USA), washed twice with ice cold PBS/
FACS and maintained in ice until flow cytometry analysis.
Induction of MDR1-Pgp expression in MDR cells
For the evaluation of the induction of MDR phenotype,
CEM-VBL10 cells in exponential phase of growth were
collected, extensively washed with warm RPMI-1640 and
resuspended at the concentration of 5 × 104 cells/mL
in BM alone, or in the presence of different VBL con-
centrations (from 100 ng/mL to 12.5 ng /mL) or RALT
(from 100 μg/mL to 12.5 μg/mL) and were seeded in
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At the end of the incubation, the cells were harvested,
washed with BM alone, and incubated with 12.5 μg/mL
of mAb MM4.17. After 30 min of incubation at 4°C, the
cells were washed, pelleted, resuspended and incubated
for an additional 30 min at 4°C in the presence of
fluorescein-conjugated goat antimouse antibody (FITC-
GAM, Cappel). After incubation, the cells were washed,
resuspended in PBS and processed for flow cytometry
analysis.
Data presentation
All the experiments were repeated at least thrice. The
significance was assessed by Student's t-test and the
criterion for statistical significance was set at P < 0.05.
Additional file
Additional file 1: Figure S1. Evaluation of VBL-bodipy and Calcein-AM
transport inhibition mediated by RALT. The efflux of the fluorescent dyes
MDR1-Pgp substrate VBL-bodipy (upper part of the Figure) and Calcein-AM
(lower part of the Figure) on CEM-VBL100 MDR cells was monitored in
drug-free conditions (red histogram), in the presence of the potent MDR1-
Pgp blocker Vrp (2.5 μg/mL) (green histogram), and following incubation
with 50 μg/mL RALT (blue histogram) dissolved in DMSO or H2O.
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